Interestingly, EGFR is over-expressed in up to 60% of ovarian epithelial malignancies, and its activation is associated with increased malignant tumor phenotype and poor patient prognosis [45, 46], while VEGF indicated lower positive expression in ovarian cancer patients (25.0%) [47]. Here, EGFR is linked to ovarian cancer.